Double boost for potential ALS treatment

The US FDA has given Orphan drug status to the PrimeC ALS therapy from Israel’s NeuroSense (see here). Meanwhile, NeuroSense has begun Phase 1 human clinical trials of PrimeC at two US sites and a Phase 2a human trial at Tel Aviv’s Sourasky Medical Center.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *